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bronchodilatorMethods: The Korean Health Insurance Review and Assessment Service databases were used.
Participants 40-years-old who had not been diagnosed with COPD between 2007 and 2008
but were diagnosed and prescribed COPD medication in 2009 were designated as newly-
diagnosed COPD patients. Patients were divided into three groups based on the use of broncho-
dilators, an inhaled long-acting bronchodilator (LA-B), an inhaled short-acting bronchodilator
(SA-B) and an oral medication (OM) group.
Results: A total of 77,480 newly-diagnosed COPD patients with a mean age of 68.5 years, among
which43,530 (56.2%)weremen,were included in the study. ERvisits andhospitalisationwere asso-
ciated with SA-B group, male gender, older age, Medicaid coverage, tertiary healthcare centre
visits and higher comorbidities. Multivariate analysis showed that the SA-B group was associated
with more ER visits, recurrent ER visits, hospitalisation and recurrent hospitalisation (adjusted
ORs [95% confidence intervals]Z 4.32 [3.93e4.75], 6.19 [5.24e7.30], 5.04 [2.95e3.39], and
8.49 [7.67e9.39], respectively) compared with the LA-B group. Medical utilisation cost was also
higher in the SA-B group.
Conclusion: Inhaled long-acting bronchodilator usewas associatedwith lower rates of hospitalisa-
tion, fewer ER visits and lowermedical costs in newly-diagnosed COPD patients in real-life clinical
practice.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a major
global health problem, with a prevalence of 5e25% among
adults worldwide. [1] COPD is among the top ten most
common chronic health conditions, and it is associated with
a marked restriction of daily activities and substantial uti-
lisation of healthcare resources. Furthermore, COPD is a
leading cause of morbidity and mortality worldwide, and is
expected to become the third leading cause of death by the
year 2020 [2,3]. Its economic burden is enormous, and
medical expenditure related to COPD is the third highest
among smoking-attributable diseases in Korea [4]. The
economic cost of COPD in the US was estimated to reach
$37.2 billion [5].
The beneficial effects of inhaled long-acting bronchodi-
lators in COPDhave beendocumented in several clinical trials
[6,7]. Treatment with inhaled long-acting bronchodilators
reduces the frequency and severity of exacerbations, and
improves health status and exercise tolerance. Accordingly,
current guidelines recommend the upfront use of inhaled
long-acting bronchodilators in symptomatic COPD patients
[8]. However, whether the effects of inhaled long-acting
bronchodilators are consistent in real practice as those re-
ported in clinical trials is not clear. Clinical trials recruit only
limited groups of patients Furthermore, although the cost-
effectiveness of bronchodilator therapy was demonstrated
in patients with asthma in a nationwide study [9], their eco-
nomic outcome in patients with COPD is still ambiguous.
We analysed the clinical impact of medications in newly-
diagnosed COPD patients using a database from the Korean
Health Insurance Review and Assessment (HIRA) Service.
Korea has a unique compulsory health insurance system,
and all medical reimbursement records for the entire
Korean population are maintained in a database, which can
therefore be used to assess the nationwide impact of an
illness and consequent health care use [10,11]. We used
this database to examine the association between medi-
cations prescribed and the utilisation of healthcare services
in newly-diagnosed COPD patients.Methods
Patient population
The databases of the Korean HIRA from January 2007 to
December 2010 were analysed. Patients with COPD as a
principal or secondary diagnosis were identified by
searching for codes of the International Classification of
Diseases, Tenth Revision (ICD-10), medication information
and demographic characteristics. COPD was defined by the
following criteria: 1) age  40-years-old; 2) ICD-10 codes
for COPD (J42-J44, except J430); and 3) use of one or more
COPD medications at least twice per year. COPD medica-
tions included 1) inhaled long-acting muscarinic antagonists
(LAMA); 2) inhaled long-acting b2 agonists (LABA); 3)
inhaled corticosteroids (ICS); 4) ICS plus LABA; 5) inhaled
short-acting muscarinic antagonists (SAMA); 6) inhaled
short-acting beta-2 agonists (SABA); 7) methylxanthines; 8)
oral corticosteroids; and 9) systemic beta agonists. Newly-
diagnosed COPD patients were those who had not been
registered as ‘COPD’ (ICD-10, J42-44) and had not been
prescribed a COPD medication for the past 2 years
(2007e2008), but did fulfil the definition of COPD from
January to December 2009.
Patients who had received more than one reimburse-
ment because of cancer (ICD-10: C00.x-C97.x), renal failure
(N17.x-N19.x), and/or cerebrovascular disease (I60.x-I69.x)
were excluded from this study because it was difficult to
distinguish between the medical costs associated with the
treatment of these diseases and those of COPD-related
services.Study design
A retrospective cohort consisting of newly-diagnosed COPD
patients was constructed and the healthcare utilisation
data corresponding to 1 year after fulfilment of the COPD
definition for each patient was analysed. Newly-diagnosed
COPD patients were divided into three groups, an inhaled
Medication in new COPD patients 155long-acting bronchodilator (LA-B) group, an inhaled short-
acting bronchodilator (SA-B) group, and the oral medication
only (OM) group. The LA-B group included patients who had
been prescribed inhaled long-acting bronchodilators as
initial medication and at least two or more separate times
during 1 year follow-up. The SA-B group included patients
whose prescription included bronchodilators or ICS, but
inhaled long-acting bronchodilators were not used as initial
medications or were used less than two separate times. The
OM group included patients whose prescription did not
include bronchodilators or ICS.
Only COPD-related healthcare utilisation and costs dur-
ing the study period were included in the analysis. Medical
utilisation and costs were excluded from the analysis if they
were not considered to be COPD-related, even when pa-
tients who met the COPD definition used medical services.
Only COPD-related medications (including COPD medica-
tions defined above and mucolytics, anti-tussives and
nonsteroidal anti-inflammatory inhalants) were analysed.
For outpatient services, analysis was confined to visits in
which the principal or secondary diagnosis was COPD (ICD-
10: J42-44, except J430) or a COPD-related disease
including pneumonia (ICD-10: J12.x-J17.x), pulmonary
thromboembolism (ICD-10: I26.0 and I26.9), dyspnoea (ICD-
10: R06.0) or acute respiratory distress syndrome (ICD-10:
J80). High medical utilisation cost was defined as that
incurred by patients at the top 20th percentile of total
medical costs including medications, and medical and
radiologic examination at outpatient and inpatients ser-
vices. The National Evidence-Based Healthcare Collabo-
rating Agency Ethics Committee of Korea approved the
present study (PIRB11-022). The requirement for informed
consent from the patients included in the study was waived
by the ethical review board.
Statistical analysis
Data were analysed using the SAS statistical program (ver.
9.2 [SAS Institute]). Frequencies and percentages were
calculated to compare variables among the LA-B, SA-B, and
OM groups; differences among the three groups were
assessed using the c2 test for categorical data and the
multivariate analysis of variance (ANOVA) for continuous
data. Univariate logistic regression analysis was performed
to understand the relationship between healthcare uti-
lisation (ER visits, hospitalisation, and medical costs) and
medications in newly-diagnosed patients with COPD, and
multiple logistic regression analysis was performed with
adjustment for several confounding factors. Medication-
related costs incurred by newly-diagnosed COPD patients
were calculated for each type of healthcare centre.
Results
Baseline characteristics
A total of 77,480 newly-diagnosed COPD patients with a
mean age of 68.5 years old were identified during the
relevant period. Of these, 43,530 (56.2%) were men. The
most common comorbidity was hypertension with a prev-
alence of 24.0%. A total of 10,572 (13.6%) patientsreceived Medicaid coverage and more than half of the
patients visited a primary care hospital service at initial
diagnosis.
Patients were divided into three groups as defined
above: the LA-B group included 12,115 patients, the SA-B
group included 5173 patients, and the OM group included
60,192 patients. The LA-B group included a higher propor-
tion of men. The mean age was higher in the SA-B group.
Patients in the SA-B and LA-B groups required hospital-
isation more often than patients in the OM group. Comor-
bidities and Medicaid coverage were more prevalent in the
SA-B group. More patients in the LA-B group utilised tertiary
healthcare centres at initial diagnosis than patients in the
SA-B or OM groups (Table 1).
Risk factors for emergency room (ER) visits and
hospitalisation
On univariate analysis, ER visits were associated with the
SA-B group, male gender, older age, Medicaid coverage,
tertiary care hospital visit at initial diagnosis, and high
Charlson comorbidity index. After adjusting for these sig-
nificant risk factors, ER visits were still significantly asso-
ciated with the SA-B and OM groups with odds ratios (ORs)
of 4.32 (95% confidence interval [CI] 3.93e4.75) and 1.31
(95% CI 1.22e1.41), respectively, compared with the LA-B
group. Recurrent ER visits (2/yr) were associated with the
same risk factors as those of ER visits in the univariate
analysis. After adjusting for these factors, recurrent ER
visits were also significantly associated with the SA-B and
OM groups with ORs of 6.19 (95% CI, 5.25e7.30) and 1.21
(95% CI, 1.04e1.41), respectively (Table 2).
Hospitalisation was significantly associated with the SA-B
group, male gender, Medicaid coverage, tertiary care hos-
pital visit at initial diagnosis, and high Charlson comorbidity
index in univariate analysis. After adjusting for these sig-
nificant risk factors, hospitalisation was still significantly
associated with the SA-B and OM groups with ORs of 5.04
(95% CI, 4.65e5.46) and 1.66 (95% CI, 1.57e1.75), respec-
tively, compared with the LA-B group. Recurrent hospital-
isation was associated with the same risk factors as those of
hospitalisation in univariate analysis. After adjusting for
these factors, recurrent ER visits were significantly associ-
ated with the SA-B and OM groups with ORs of 8.49 (95% CI,
7.67e9.39) and 1.57 (95% CI, 1.44e1.71), respectively
(Table 3).
Risk factors for high medical utilisation cost
High medical utilisation cost (total medical costs including
medications, and medical and radiologic examination) was
associated with the SA-B group, male gender, older age,
Medicaid coverage, tertiary healthcare centre visit at initial
diagnosis, and high Charlson comorbidity index. After
adjusting for these significant factors, the SA-B and OM
groups were significantly associated with high medical uti-
lisation cost with ORs of 4.48 (95% CI, 4.13e4.87) and 1.38
(95% CI, 1.30e1.46), respectively (Table 4). Mean medical
utilization cost was the highest in SA-B, which was mainly
associated with high admission and medication costs
(Fig. 1).
Table 1 Baseline characteristics of newly-diagnosed COPD patients.
LA-B
(long-acting included)
N Z 12,115
SA-B
(long-acting not included)
N Z 5173
OM
(oral medication only)
N Z 60,192
Total
N Z 77,480
P-value
Sex, n (%)
Male 8663 (71.5) 2925 (56.5) 31,942 (53.1) 43,530 (56.2) <0.001
Female 3452 (28.5) 2248 (43.5) 28,250 (46.9) 33,950 (43.8)
Age, mean  SD 66.0  10.5 70.3  11.2 68.9  11.0 68.5  11.0 <0.001
Recent hospitalisation
before diagnosis
(1 yr), n (%)
1713 (14.1) 748 (14.5) 6118 (10.2) 8579 (11.1) <0.001
Never 10,402 (85.9) 4425 (85.5) 54,074 (89.8) 68,901 (88.9)
Ever 1713 (14.1) 748 (14.5) 6118 (10.2) 8579 (11.1)
Comorbidity, n (%)
Hypertension 2619 (21.6) 1520 (29.4) 14,473 (24.0) 18,612 (24.0) <0.001
Ischemic heart disease 820 (6.8) 543 (10.5) 4442 (7.4) 5805 (7.5) <0.001
Osteoporosis 365 (3.0) 273 (5.3) 2708 (4.5) 3346 (4.3) <0.001
Depressive disorder 167 (1.4) 112 (2.2) 856 (1.4) 1135 (1.5) <0.001
Arthritis 179 (1.5) 174 (3.4) 2379 (4.0) 2732 (3.5) <0.001
Diabetes mellitus 1284 (10.6) 812 (15.7) 7129 (11.8) 9225 (11.9) <0.001
Congestive heart failure 401 (3.3) 431 (8.3) 3091 (5.1) 3923 (5.1) <0.001
Anaemia 163 (1.3) 128 (2.5) 1019 (1.7) 1310 (1.7) <0.001
Metabolic syndrome 802 (6.6) 303 (5.9) 3306 (5.5) 4411 (5.7) <0.001
Insurance type, n (%) <0.001
Health insurance 10,702 (88.3) 4236 (81.9) 51,970 (86.3) 66,908 (86.4)
Medicaid 1413 (11.7) 937 (18.1) 8222 (13.7) 10,572 (13.6)
Initial health care system, n (%) <0.001
Primary 1435 (11.9) 2121 (41.0) 39,411 (63.9) 42,967 (55.5)
Secondary 939 (7.8) 1000 (19.3) 6525 (10.8) 8464 (10.9)
Tertiary 9741 (80.4) 2052 (39.7) 14,256 (23.7) 26,049 (33.6)
LA-B, long-acting bronchodilator included in initial prescription; SA-B, only-shorting bronchodilator included in initial prescription or
long-acting bronchodilators were prescribed less than twice; OM, bronchodilators were not prescribed.
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The medication cost (cost for drugs) per person was higher
for inhaled long-acting bronchodilators, such as LAMA and
ICS/LABA, during the study period (Table 5).Discussion
The results of the present study show that the use of
inhaled long-acting bronchodilators is associated with
fewer ER visits, a lower rate of hospitalisation and lower
medical utilisation costs in newly-diagnosed COPD patients.
The lower medical utilisation costs in the LA-B group were
associated with the lower number of ER visits and hospi-
talisations because the cost of inhaled long-acting bron-
chodilators is higher than that of inhaled short-acting
bronchodilators or oral medications.
Inhaled long-acting bronchodilators are used in COPD
patients to reduce symptoms, reduce the frequency and
severity of exacerbations, and improve health status and
exercise tolerance. Inhaled long-acting bronchodilators
have been shown to be superior to short-acting broncho-
dilators (taken as needed) for reducing COPD symptoms and
the frequency of exacerbations [12,13]. LAMA use was
shown to decrease the incidence of COPD exacerbationsand related health care utilisation in patients with moder-
ate to severe COPD [14]. In a subsequent study that
included long-term follow-up, therapy with LAMA was
associated with the improvement of lung function, quality
of life, and reduced frequency of exacerbations [7]. LABA
treatment improved airflow obstruction, the control of
symptoms, and health status in patients with COPD
[15e17]. When administered in combination with ICS, LABA
resulted in better control of symptoms and improved lung
function, and was not associated with a greater risk of side
effects than the use of either component alone [18]. LABA
plus ICS treatment was associated with improved survival of
patients with COPD with marginal significance [6]. A new
LABA, indacaterol, was recently shown to improve symp-
toms, health status and lung function [19e21]. The results
of clinical trials suggest that inhaled long-acting broncho-
dilators are recommended as the initial treatment of choice
for symptomatic COPD patients except in the subgroup of
patients with low risk and good lung function [8]. Even for
this subgroup, inhaled long-acting bronchodilators may still
be effective, in particular if the symptoms persist after
short-acting bronchodilator inhalation. [22]
Exacerbations requiring ER visit and hospitalisation ac-
count for the highest healthcare-related expenses in pa-
tients with COPD [23,24]. Although mild exacerbations can
often be treated on an outpatient basis with oral
Table 2 Risk factors for ER visits in newly-diagnosed COPD patients.
Patients with ER visits Patients with recurrent ER visits (2/yr)
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Patient group
LA-B 1(ref) 1(ref) 1(ref) 1(ref)
SA-B 2.87 (2.64e3.13) <0.001 4.32 (3.93e4.75) <0.001 5.15 (4.41e6.02) <0.001 6.19 (5.25e7.30) <0.001
OM 0.70 (0.66e0.75) <0.001 1.31 (1.22e1.41) <0.001 0.73 (0.63e0.84) <0.001 1.21 (1.04e1.41) 0.01
Sex
Female 1(ref) 1(ref) 1(ref) 1(ref) <0.001
Male 1.48 (1.41e1.56) <0.001 1.31 (1.24e1.38) <0.001 1.55 (1.40e1.72) <0.001 1.42 (1.27e1.59) <0.001
Age 1.04 (1.04e1.04) <0.001 1.04 (1.03e1.04) <0.001 1.04 (1.04e1.05) <0.001 1.03 (1.02e1.03) <0.001
Insurance type
Medicaid 1(ref) 1(ref) 1(ref) 1(ref)
Health insurance 0.67 (0.63e0.72) <0.001 0.86 (0.80e0.92) <0.001 0.60 (0.53, 0.67) <0.001 0.81 (0.72e0.93) 0.002
Initial healthcare service
Primary þ Secondary 1(ref) 1(ref) 1(ref) 1(ref)
Tertiary 5.63 (5.34e5.94) <0.001 5.84 (5.52e6.19) <0.001 5.80 (5.19e6.48) <0.001 5.12 (4.56e5.75) <0.001
Charlson comorbidity index
0e1 1(ref) 1(ref) 1(ref) 1(ref)
2 2.70 (2.55e2.86) <0.001 2.44 (2.30e2.59) <0.001 3.43 (3.04e3.88) <0.001 2.88 (2.53e3.26) <0.001
3 4.67 (4.39e4.98) <0.001 3.95 (3.68e4.23) <0.001 7.64 (6.75e8.64) <0.001 5.80 (5.10e6.60) <0.001
ER, emergency room; OR, odds ratio; LA-B; CI, confidence interval; long-acting bronchodilator included in initial prescription; SA-B, only-shorting bronchodilator included in initial
prescription or long-acting bronchodilators were prescribed less than twice; OM, bronchodilators were not prescribed.
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Table 3 Risk of hospitalisation for newly-diagnosed COPD patients.
Patients with hospitalisation Patients with recurrent hospitalisation (2/yr)
Crude OR
(95% CI)
P-value Adjusted OR
(95% CI)
P-value Crude OR
(95% CI)
P-value Adjusted OR
(95% CI)
P-value
Patient group
LA-B 1(ref) 1(ref) 1(ref) 1(ref)
SA-B 3.16 (2.95e3.39) <0.001 5.04 (4.65e5.46) <0.001 6.89 (6.29e7.55) <0.001 8.49 (7.67e9.39) <0.001
OM 0.93 (0.89e0.97) 0.002 1.66 (1.57e1.75) <0.001 1.20 (1.11e1.29) <0.001 1.57 (1.44e1.71) <0.001
Sex
Female 1(ref) 1(ref) 1(ref) 1(ref)
Male 1.24 (1.20e1.28) <0.001 1.16 (1.12e1.21) <0.001 1.19 (1.14e1.25) <0.001 1.25 (1.18e1.32) <0.001
Age 1.04 (1.04e1.04) <0.001 1.04 (1.03e1.04) <0.001 1.04 (1.04e1.04) <0.001 1.03 (1.03e1.04) <0.001
Insurance type
Medicaid 1(ref) 1(ref) 1(ref) 1(ref)
Health insurance 0.51 (0.49e0.53) <0.001 0.62 (0.59e0.65) <0.001 0.40 (0.37e0.42) <0.001 0.49 (0.46e0.53) <0.001
Initial healthcare service
Primary þ
Secondary
1(ref) 1(ref) 1(ref) 1(ref)
Tertiary 3.70 (3.57, 3.83) <0.001 4.63 (4.44e4.83) <0.001 2.63 (2.51e2.76) <0.001 2.72 (2.58e2.88) <0.001
Charlson comorbidity index
0e1 1(ref) 1(ref) 1(ref) 1(ref)
2 3.13 (3.00e3.25) <0.001 2.99 (2.86e3.12) <0.001 3.44 (3.24e3.65) <0.001 3.04 (2.85e3.23) <0.001
3 6.11 (5.82e6.41) <0.001 5.61 (5.32e5.92) <0.001 8.02 (7.53e8.53) <0.001 6.71 (6.27e7.17) <0.001
OR, odds ratio; LA-B; CI, confidence interval; long-acting bronchodilator included in initial prescription; SA-B, only-shorting bronchodilator included in initial prescription or long-acting
bronchodilators were prescribed less than twice; OM, bronchodilators were not prescribed.
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Table 4 Risk factors of high medical utilisation cost.
Crude OR (95% CI) P-value Adjusted OR (95% CI) P-value
Patient group
LA-B 1 (ref) 1 (ref)
SA-B 2.85 (2.66e3.05) <0.001 4.48 (4.13e4.87) <0.001
OM 0.78 (0.75e0.82) <0.001 1.38 (1.30e1.46) <0.001
Sex
Female 1 (ref) 1 (ref)
Male 1.30 (1.25e1.35) <0.001 1.20 (1.15e1.25) <0.001
Age 1.040 (1.038e1.042) <0.001 1.034 (1.032e1.036) <0.001
Insurance type
Medicaid 1 (ref) 1 (ref)
Health insurance 0.49 (0.47e0.52) <0.001 0.60 (0.57e0.63) <0.001
Initial healthcare system
Primary þ Secondary 1 (ref) 1 (ref)
Tertiary 4.14 (3.99e4.29) <0.001 4.91 (4.70e5.12) <0.001
Charlson comorbidity index
0e1 1 (ref) 1 (ref)
2 3.17 (3.04e3.30) <0.001 3.05 (2.91e3.19) <0.001
3 6.40 (6.09e6.72) <0.001 6.01 (5.68e6.35) <0.001
OR, odds ratio; LA-B; CI, confidence interval; long-acting bronchodilator included in initial prescription; SA-B, only-shorting broncho-
dilator included in initial prescription or long-acting bronchodilators were prescribed less than twice; OM, bronchodilators were not
prescribed.
Medication in new COPD patients 159corticosteroids and/or antibiotics, patients frequently
present to the ER or are admitted to the hospital for
moderate or severe exacerbations requiring more intensive
medical treatment. The cost of COPD-related hospital-
isations and ER visits was estimated to be $10 billion in 2003
[25], and exacerbations account for nearly 70% of the direct
healthcare costs of COPD [26]. Therefore, the severity ofFigure 1 Component of medical utilization cost. LA-B, long-
acting bronchodilator group; SA-B, short-acting bronchodilator
group; OM, oral medication only group.exacerbations requiring hospitalisation is correlated with
increased healthcare-related costs [27], and consequently,
a reduction in the frequency and severity of COPD exac-
erbations could significantly reduce healthcare spending
related to COPD [28]. Factors associated with higher total
healthcare costs extend beyond COPD to comorbidities such
as cardiovascular disease and diabetes [28]. In our study,
the SA-B group was associated with a greater risk of
increased medical expenses despite the lower cost of the
medication, which can be explained by the costs related to
ER visits and hospitalisations.
The effect of inhaled long-acting bronchodilators on
decreasing the frequency and severity of exacerbations has
been shown in several clinical trials. However, because
these trials included a restricted group of patients, gen-
eralising the results should be done with caution [12,13]. In
the present study, the use of inhaled long-acting broncho-
dilators was found to be associated with fewer ER visits, a
lower rate of hospitalisation and lower medical costs based
on the data extracted from a nationwide database of
medical reimbursement records.
The present study had several limitations. First, infor-
mation on the risk factors associated with COPD or its
exacerbation, particularly smoking, compliance, lung
function, exacerbation history and quality of life [29,30], is
not available in the Korean HIRA database. Although we
attempted to include variables such as age, social class
associated with insurance type, and comorbidities as po-
tential risk factors, causal inference can be difficult. Pre-
vious studies with large database could also have a similar
limitation [28,31e33]. To select proper study population,
we excluded patients who used COPD medications less than
twice in a year. LA-B group also did not include patients
with prescription of inhaled long-acting bronchodilator less
than twice in a year. Second, this study focused on initial
Table 5 Medication costs of newly-diagnosed COPD patients by type of hospital (per person, per year, USD).
Healthcare centre Primary (n Z 48,077a) Secondary (n Z 12,625a) Tertiary (n Z 42,524a)
LAMA 116.2  110.6 121.3  300.7 168.3  315.3
ICS þ LABA 82.7  82.6 93.7  94.3 142.3  128.2
LTRA 37.8  64.1 51.4  73.2 103.7  115.5
ICS 9.0  19.9 20.0  33.0 32.0  47.9
SABA þ SAMA 21.5  37.9 17.2  15.4 18.6  19.8
SAMA 5.3  22.5 10.0  16.5 14.9  24.8
SABA 3.7  9.3 5.5  11.7 7.3  13.2
Theophyllline 5.3  11.7 9.0  16.0 21.6  29.5
Systemic ß2 agonist 5.2  16.1 8.7  19.8 18.3  35.3
OCS 1.7  5.4 1.8  5.7 3.4  10.5
LAMA, long-acting muscarinic antagonist; ICS, inhaled corticosteroid; LABA, long-acting b2 agonist; LTRA, leukotriene receptor antag-
onist; SABA, short-acting b2 agonist; SAMA, short-acting muscarinic antagonist; OCS, oral corticosteroid.
a Groups are not exclusive to each other.
160 J. Kim et al.medication in “newly-diagnosed” COPD patients. Future
study is necessary to confirm whether this result is consis-
tent in all COPD patients. Third, the definition of COPD in
this study was somewhat arbitrary. COPD was defined based
on the prescription of COPD medication at 2 separate
times and ICD-10 diagnostic codes; because lung function
tests were not available. We assume that patients enrolled
based on these criteria of our study could be considered as
part of the ‘practical’ population that is managed as COPD.
The ratio of women COPD (43.8%) in this study was higher
than that of previous studies about COPD prevalence in
Korea [34,35]. It is hard to explain the cause of difference
exactly, but it can be suggested that women usually feel
symptoms more severely and could visit hospital more often
than men [36,37]. The Korean National Health Insurance
currently only reimburses the cost of inhaled long-acting
bronchodilators in patients with forced expiratory volume
in 1 s (FEV1) per forced vital capacity (FVC)  0.7, implying
that physicians prescribe inhaled long-acting bronchodila-
tors only on the basis of lung function tests. Therefore, our
results provide additional evidence supporting the clinical
use of inhaled long-acting bronchodilators, despite the
above limitations. In addition, the data obtained from the
insurance database possess a range and depth not neces-
sarily available from other resources.
Inhaled long-acting bronchodilators were prescribed
mostly in tertiary healthcare centres in this study. This
could be related to the fact that severe patients usually
visit tertiary referral hospitals, and inhaled long-acting
bronchodilators are recommended initially in patients with
obvious symptoms, high risk and impaired lung function
[38]. Furthermore, an increased number of ER visits, hos-
pitalisations and high medical utilisation costs were asso-
ciated with tertiary healthcare centre patients. Despite of
this association, the LA-B was associated with lower ER
visits, hospitalization and inversely associated with high
medication utilisation costs.
Prescribing habits for COPD patients remain a concern in
Korea. Many patients with COPD were prescribed only oral
medication despite current guidelines [8]. This may be a
result of patient preference and demand which affects
prescribing habits [39]. Diagnosis of COPD in this study, as in
many others looking at disease databases, still needsimprovement; only 32.1% of these patients had pulmonary
function tests during the course of the study period.
Male sex, older age, Medicaid coverage and comorbid-
ities were also associated with ER visits and hospitalisation
in this study. Among these factors, older age and Medicaid
coverage are reported to be associated with exacerbations
[30,40], and comorbidities such as cardiovascular compli-
cations are an important cause of mortality in COPD pa-
tients [41]. Sex-based differences in the incidence of
exacerbations are still controversial. [29]
In conclusion, the inclusion of inhaled long-acting
bronchodilators in the initial treatment was associated
with a lower rate of ER visits, hospitalisations and lower
medical costs in newly-diagnosed COPD patients. In a
nationwide cohort including ‘practical’ patients with COPD,
the use of long-acting bronchodilators showed beneficial
effects similar to those reported in clinical trials.
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